Leiden: gateway to Europe
Leiden is the best choice for pharmaceutical companies to set up their business. Over the past 25 years the city’s Bio Science Park has produced many innovative discoveries and offers benefits including an attractive environment, talent, technology and connectivity.
|
| Leiden offers life science companies an attractive location in the existing and new bioscience park areas. |
|
| A number of new technologies and products have been discovered in Leiden, proving its commercial potential. |
| |
| |
Leiden Bio Science
Park is the leading life
science cluster in the
Netherlands and ranks among
the top five most successful
science parks in Europe. For
25 years it has been fully
dedicated to biomedical
life science and offers
opportunities for start-ups
and established companies.
The Leiden Bio Science Park
features over 60 dedicated
medical life science
companies, the largest
number of bioscience
start-ups in the Netherlands,
several multinationals and
internationally acclaimed
knowledge institutions.
This is an excellent
environment for science and
business to flourish.
Talent
Because of its outstanding
research, excellent facilities
and healthy business climate,
Leiden is home to a number
of leading innovative
companies, such as Centocor,
Pharming, Galapagos,
to-BBB and Crucell.
Several renowned research
institutions including
the Faculty of Science
at Leiden University,
the Leiden University
Medical Centre (LUMC),
TNO Quality of Life,
the Centre for Human
Drug Research and Top
Institute Pharma are also
based at the Leiden Bio
Science Park.
Technology and
connectivity
A key benefit of Leiden Bio
Science Park is its ability
to commercialise
biomedical knowledge.
The park has a strategy
for identifying the most
promising research
findings at its knowledge
institutions and strongly
encourages commercial
development, by seeking
suitable business partners,
arranging financial and
legal support, and so on.
Since 1984, the Leiden
Bio Science Park has been
developed using a so-called
‘triple-helix’ model, where
companies and knowledge
institutions work closely
with the government. The
knowledge cluster has
facilitated the development
of a dynamic and effective
knowledge cluster,
profitable business and
continuous growth.
Made in Leiden
Life sciences research in
Leiden, academic and
industrial, has already
yielded a number of new
technologies and products.
These discoveries have often
sprung from cooperation
with other groups based
outside of Leiden. A number
of examples of products
‘made in Leiden’ illustrate
the park’s commercial
potential:
- Factor-V Leiden, the
most prevalent genetic
risk factor for venous
thrombosis, was
discovered at the LUMC
- Remicade®, produced by
Centocor, is a new type
of monoclonal antibody
used in the treatment of
auto-immune diseases
- Quinvaxem®, produced
by Crucell, is a vaccine
used for protection
against five important
childhood diseases
- OctoPlus developed
Locteron®, a novel
interferon alpha
combined with
proprietary drug delivery
technology and indicated
for chronic hepatitis C.
Expansion of the park will
open up more opportunities
for companies working in
the life sciences and R&D
institutes to establish
themselves in an attractive
location. There is room to
take up residence in the
existing park area, and
opportunities to settle in the
new 36-hectare park area
under development. |
 |
Company profile
The Leiden Bio Science
Park welcomes international
biotechnology and pharmaceutical
companies wishing to enter
the European market or open
European premises. For more
information, visit:
www.leidenbiosciencepark.nl.
|
